@vidpok45 re pursuing alz: I think the bigger issue is that the company is running out of money and time. Not sure if the company has the resources (people/time/money) to go after this on its own.
Yes, HB's resistance to pursuing this indication for AZ is troubling when this could be the most meaningful use of Ponatinib. If it requires that HB leave for this to be pursued then I am on board but somehow I think HB will come around on this. Hope to hear him say something sensible about this on the CC.
News 
Market Data 
Discover 
AI
